Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.62 |
| ▸ | CDK2 | P24941 | 4/20 | 0.62 |
| ▸ | CCNK | O75909 | 2/20 | 0.62 |
| ▸ | CCND3 | P30281 | 2/20 | 0.62 |
| ▸ | CDK9 | P50750 | 2/20 | 0.62 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | WEE1 | P30291 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 11/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1606535 | 0.92 | CCNK (0.58) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL1606568 | 0.90 | CCNA2 (0.60) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL1605811 | 0.89 | PDGFRB (0.53) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL1607193 | 0.87 | PDGFRA (0.61) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL1605529 | 0.84 | CCNA2 (0.66) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL1607653 | 0.82 | BRD4 (0.66) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL1607935 | 0.82 | BRD4 (0.57) | ALKBRD4PTK2JAK2 | |
| SCHEMBL1607293 | 0.79 | BRD4 (0.63) | WEE1ALKBRD4JAK2FLT3 | |
| SCHEMBL1606530 | 0.78 | BRD4 (0.53) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL1605710 | 0.77 | JAK3 (0.43) | CCNA2CDK2CCNKCDK9PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304422-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | claimed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | claimed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | claimed |
| WO-2008118822-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-8304422-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008118822-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CCNA2 1836/4885CDK2 236/4885CCNK 753/4885 |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | CCNA2 4241/4885CDK2 1590/4885CCNK 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.